Key result
CYP2C19 loss-of-function alleles linked to ~2.2-fold higher recurrent stroke risk on clopidogrel.
Why the study?
The aggregated risk of recurrent stroke in stroke/TIA patients carrying CYP2C19 LoF alleles taking clopidogrel had not been investigated recently, with limited available research.
Does the presence of CYP2C19 loss-of-function alleles increase the risk of recurrent stroke or adverse vascular events in stroke/TIA patients treated with clopidogrel?
Meta-Analysis (n=9,443)
Does the presence of CYP2C19 loss-of-function alleles increase the risk of recurrent stroke or adverse vascular events in stroke/TIA patients treated with clopidogrel?
Stroke and TIA patients carrying CYP2C19 loss-of-function alleles have a significantly higher risk of recurrent stroke when treated with clopidogrel, particularly in Asian populations, suggesting a benefit for genotype-guided antiplatelet therapy.
Answers are grounded in this paper and cite their sources.
May support CYP2C19 genotyping to guide antiplatelet selection post-stroke; extends coronary associations to cerebrovascular events.
The aggregated risk of recurrent stroke in stroke/transient ischemic attack (TIA) patients carrying CYP2C19 LoF alleles who take clopidogrel has not been investigated recently, and the available research is limited. This study aimed to perform an updated meta-analysis to assess the association between CYP2C19 LoF alleles and the risk of recurrent stroke in patients taking clopidogrel. Databases were searched for the literature on eligible studies. The end points were recurrent stroke, composite vascular events, and bleeding events. Odds ratios (ORs) were calculated using RevMan software, where p < 0.05 was considered statistically significant. Patients carrying CYP2C19 LoF alleles who were treated with clopidogrel had a significantly increased risk of recurrent ischemic stroke compared with non-carriers (OR 2.18, 96% CI 1.80-2.63; p < 0.00001). The risk of recurrent stroke was only significantly different in Asian patients (OR 2.29, 96% CI 1.88-2.80; p < 0.00001) but not in patients of other ethnicities; however, there were a limited number of studies in other ethnic groups. Both observational studies (OR 2.83, 96% CI 2.20-3.65; p < 0.00001) and RCTs (OR 1.48, 96% CI 1.10-1.98; p = 0.009) found associations with a significantly increased risk of recurrent ischemic stroke. Asian stroke patients or TIA patients carrying CYP2C19 LoF alleles and taking clopidogrel were at a significantly higher risk of recurrent ischemic stroke than non-carriers. Significantly increased risk of recurrent ischemic stroke was found in both observational studies and RCTs.
No takes yet. Share an insight, caveat, or question.
Biswas et al. (2024) conducted a meta-analysis in Ischemic stroke or transient ischemic attack (TIA) (n=9,443). CYP2C19 loss-of-function (LoF) alleles vs. CYP2C19 wild-type genotype (non-carriers) was evaluated on Recurrent ischemic stroke (OR 2.18, 95% CI 1.80-2.63, p=<0.00001). Carrying CYP2C19 loss-of-function alleles increased the risk of recurrent ischemic stroke by over twofold in stroke or TIA patients treated with clopidogrel.
Synapse has enriched 10 related papers. Consider them for comparative context: